Coya Therapeutics (NASDAQ:COYA – Get Free Report) and Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.
Earnings and Valuation
This table compares Coya Therapeutics and Xenon Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coya Therapeutics | $7.95 million | 13.72 | -$21.23 million | ($1.07) | -4.35 |
| Xenon Pharmaceuticals | $7.50 million | 725.41 | -$345.91 million | ($4.74) | -11.87 |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Coya Therapeutics and Xenon Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coya Therapeutics | 1 | 0 | 6 | 0 | 2.71 |
| Xenon Pharmaceuticals | 1 | 0 | 14 | 2 | 3.00 |
Coya Therapeutics currently has a consensus price target of $15.33, suggesting a potential upside of 229.75%. Xenon Pharmaceuticals has a consensus price target of $77.13, suggesting a potential upside of 37.05%. Given Coya Therapeutics’ higher possible upside, research analysts plainly believe Coya Therapeutics is more favorable than Xenon Pharmaceuticals.
Risk & Volatility
Coya Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Profitability
This table compares Coya Therapeutics and Xenon Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coya Therapeutics | -270.22% | -52.05% | -46.34% |
| Xenon Pharmaceuticals | N/A | -43.98% | -41.72% |
Institutional and Insider Ownership
39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Xenon Pharmaceuticals beats Coya Therapeutics on 8 of the 14 factors compared between the two stocks.
About Coya Therapeutics
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
